<circle stroke="#1e77f9" class="srdi68r9" cx="25" cy="25" r="20" fill="none" stroke-width="5">

Nanobiotix initiated with a Buy at Guggenheim

PremiumThe Fly

2M ago

Nanobiotix initiated with a Buy at Stifel

PremiumThe Fly

5M ago

Nanobiotix announces new data from Study 1100

PremiumThe Fly

5M ago

Nanobiotix provides update on NBTXR3 collaboration

PremiumThe Fly

6M ago

PremiumThe FlyNanobiotix announces FDA issuance of Study May Proceed Letter for NBTXR3 study

6M ago

The Fly

Nanobiotix completes dose escalation of of radioenhancer NBTXR3 study

7M ago

Nanobiotixachieves $20M milestone payment from Johnson & Johnson subsidiary

The Fly

Nanobiotixachieves $20M milestone payment from Johnson & Johnson subsidiary

10M ago

Nanobiotix says LianBio enters NBTXR3 development pact with Johnson & Johnson

PremiumThe Fly

11M ago

Nanobiotix initiated with an Outperform at Leerink

LIAN

PremiumThe Fly

11M ago

Nanobiotix announces pricing of global share offering

PremiumThe Fly

1y ago

Nanobiotix announces launch of additional $30M global follow-on offering

PremiumThe Fly

1y ago

PremiumThe FlyNanobiotix announces updated data from two presentations at ESMO

1y ago

The Fly

Nanobiotix announces NBTXR3 for elderly patients presentation at ASTRO

1y ago

The Fly

Nanobiotix announces new clinical data from NBTXR3 study

1y ago

Nanobiotix announces expiration of HSR antitrust waiting period for NBTXR3 pact

PremiumThe Fly

1y ago

Nanobiotix; 1st patient injected in study evaluating activated NBTXR3 for cancer

PremiumThe Fly

1y ago

Nanobiotix jumps 56% to $7.85 after global licensing pact with Janssen

PremiumThe Fly

1y ago

Nanobiotix announce global licensing pact with Johnson & Johnson for NBTXR3

PremiumThe Fly

1y ago

PremiumThe FlyNanobiotix price target lowered to EUR 9 from EUR 25 at H.C. Wainwright

2y ago

Nanobiotix reports FY22 ($1.64) vs. ($1.35) in FY21

The Fly

Nanobiotix reports FY22 ($1.64) vs. ($1.35) in FY21

2y ago